Inhibikase Therapeutics, INC DEF 14A proxy statements

Inhibikase Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026.

Inhibikase Therapeutics, Inc. has issued a supplement to its 2025 Annual Meeting proxy statement to clarify disclosures regarding proposed amendments to its 2020 Equity Incentive Plan, including an increased non-employee director award limit and an evergreen provision.

Inhibikase Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Inhibikase Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of its auditor, and approve an amendment to its equity incentive plan.

Inhibikase Therapeutics is holding a special virtual meeting on January 3, 2025, to seek stockholder approval for increasing authorized shares, amending the equity incentive plan, repricing stock options, and altering voting requirements for certain charter amendments.

Inhibikase Therapeutics has filed a definitive proxy statement with the SEC.

Inhibikase Therapeutics is holding a special meeting to seek stockholder approval for the issuance of common stock purchase warrants related to a private placement and warrant inducement.

Inhibikase Therapeutics has filed a definitive proxy statement with the SEC.

Inhibikase Therapeutics is holding a virtual annual meeting on June 7, 2024, to vote on director election, auditor ratification, equity incentive plan amendment, and certificate of incorporation amendment.